2008
DOI: 10.1002/14651858.cd006843.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Fetal fibronectin testing for reducing the risk of preterm birth

Abstract: Although FFN is commonly used in labor and delivery units to help in the management of women with symptoms of preterm labor, currently there is not sufficient evidence to recommend its use. Since this review found an association between knowledge of FFN results and a lower incidence of preterm birth before 37 weeks, further research should be encouraged.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
71
1
7

Year Published

2011
2011
2020
2020

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 153 publications
(85 citation statements)
references
References 29 publications
4
71
1
7
Order By: Relevance
“…Полученные данные еще раз подтверждают, что оценка риска у пациентов с историей преждевременных родов или потерей беременности требует тщательного наблюдения за состоянием шейки матки в сравнении с пациентами без отягощенного анамнеза по невынашиванию [2].…”
Section: Discussionunclassified
See 1 more Smart Citation
“…Полученные данные еще раз подтверждают, что оценка риска у пациентов с историей преждевременных родов или потерей беременности требует тщательного наблюдения за состоянием шейки матки в сравнении с пациентами без отягощенного анамнеза по невынашиванию [2].…”
Section: Discussionunclassified
“…2 Отделение женских болезней, "University Medical Center" Национальный научный центр материнства и детства, Астана, Казахстан.…”
Section: Cтруктура и факторы риска преждевременных родовunclassified
“…A positive fFN test in vaginal fluids is the most accurate investigation in predicting spontaneous preterm birth (PTB) within 7-10 days among women with symptoms of threatened PTD and improves the predictive value of cervical ultrasonography to identify patients at risk [84]. A fFN positive test represents a powerful marker of PTD when measured at or after 22-24 weeks of gestation in asymptomatic high-risk women [85].…”
Section: Diagnostic Toolsmentioning
confidence: 99%
“…This finding could explain why fFN has failed to change clinical practice in studies where clinicians were randomized to know the test results of fFN tests versus being blinded to the results. [24][25][26] Further research is clearly needed to identify a test that would be more effective than either phIGFBP-1 or fFN in correctly identifying women who will not deliver preterm or within a defined period. Until the time when a better test is available, institutions and clinicians must decide whether the use of either test is clinically justified in women with symptoms of preterm labor.…”
Section: Diagnostic Accuracy Of Phigfbp-1 Testing S Cooper Et Almentioning
confidence: 99%